false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - The Car ...
Combination Therapies for Cardiovascular-Kidney Ri ...
Combination Therapies for Cardiovascular-Kidney Risk Optimization: Who, When, and How?
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The speaker described a new era of combination therapies for cardiorenal-metabolic disease, emphasizing patients with overlapping type 2 diabetes and chronic kidney disease. Because cardiovascular events and death often occur before kidney failure, clinicians should identify risk early and aim to preserve kidney function—not wait until kidney failure is imminent.<br /><br />Evidence supports foundational therapies such as SGLT2 inhibitors, renin–angiotensin system inhibitors, and statins, with additional benefit from finerenone and GLP-1 therapies. Mechanistic, animal, and clinical data suggest these treatments can have complementary effects, though residual risk remains substantial. The challenge is to personalize treatment intensity: avoid both undertreatment and unnecessary medication, while improving risk assessment, sequencing, long-term safety evidence, and equitable implementation.<br /><br />A forthcoming national trial will test rapid, multidisciplinary treatment implementation in high-risk CKD. In discussion, the speaker acknowledged that pill burden can feel like failure to patients and called for better communication and, eventually, combination pills. Long-term treatment duration remains uncertain.
Asset Caption
Janani Rangaswami, MD
Meta Tag
Speaker
Janani Rangaswami
Keywords
cardiorenal-metabolic disease
type 2 diabetes
chronic kidney disease
SGLT2 inhibitors
finerenone
combination therapy
×
Please select your language
1
English